title: [The revolution in the treatment of retinal diseases: anti-VEGF treatment at the Assuta Eye Institute].
abstract: The VEGF protein (Vascular Endothelial Growth Factor) was identified in the '80s as a factor which induces proliferation of blood vessels in the body in general and in the retina in particular. Proliferative processes in retinal blood vessels, vascular permeability and induced edema which follows, frequently cause blindness in the diseases of the macula: AMD (Age-related Macular Degeneration) diabetes and retinal vascular occlusions. Since 2006, through treatment using anti-VEGF drugs--Avastin (Bevacizumab) and Lucentis (Ranibizumab) and Eylea (Aflibercept)--blindness in many patients in Israel and elsewhere was prevented. This paper reviews the treatment with anti-VEGF intraocular injections in the above mentioned diseases with reference to the growing activity at the Assuta Eye Institute.
authors.forename: Gabriel
authors.initials: G
authors.lastname: Katz
authors.forename: Chaya
authors.initials: C
authors.lastname: Zehavi
authors.forename: Giora
authors.initials: G
authors.lastname: Treister
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000068258:Bevacizumab; D006801:Humans; D056965:Injections, Intraocular; D007557:Israel; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D012164:Retinal Diseases / Q000188:drug therapy* / Q000503:physiopathology; D012171:Retinal Vessels / Q000187:drug effects / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab